Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 1110

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1
Chunk 1110
---
ovaro Cube is
actively pursuing relationships with leading academic cancer centers, pathology and imagery centers in Europe, the USA and the Middle
East. In certain cases, scopes of work are in process. This is a very attractive model for partners to be involved with Renovaro Cube
to perform multi-omics genetic analysis using liquid biopsies.

Resources

As of the year ended June 30,
2025, Renovaro Cube intends to hire additional staff to increase the speed and velocity of its organization, including the development
of the AI platform and the opportunities to deploy the AI platform for research perspective and ultimately for clinical practice and into
clinical trials. In addition, Renovaro Cube intends to build out its infrastructure by leasing space for storage, networking and hosting
facilities.

Target Market

Renovaro Cube’s intended
customers will be hospitals, clinics, insurance companies, pharmaceutical companies, biotech companies, research centers, physicians and
individual patients.

Renovaro Cube aims to utilize
its AI technology to commercialize products and test kits for healthcare providers, hospitals, clinics and doctors that will expedite
diagnosis and the selection of appropriate treatment for various types of cancer. Renovaro Cube intends to differentiate its products
based on the following factors:

    ●
    Proprietary and unique panel mining algorithms to create multiple biomarker stratifications per cancer;

    ●
    Explainable AI, offering traceability between the prediction and the exact biomarkers, panels and genes;

    ●
    Differential diagnosis, inclusion and exclusion of cancer types based on facts; and

    ●
    Precision diagnosis, with a high accuracy percentage with machine-learning tuning.

The multi-omic design of Renovaro
Cube’s AI platform enables the use of different molecular layers, such as epigenomics, transcriptomics, and metabolomics, together
with genomics and clinical data.

Panel Mining 

The unique panel mining technique
in Renovaro Cube’s technology repeatedly investigates genes to identify relevant biomarkers. The proprietary technique in Renovaro
Cube’s technology not only searches for individual biomarkers, but also integrates validated panels for different cancer types into
the “RenovaroCube” machine learning library. This process enables precision diagnosis, by including one cancer and excluding
others based on statistically, scientifically and clinically validated machine-learning panels.

Panel mining is designed to combine
biomarkers into panels in such a way that the final panel meets:

    ●
    performance metric criteria;

    ●
    technical criteria,